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SUMMARY 
A sensitive and specific procedure using high-performance liquid chromatography (HPLC) was 
developed for the quantification of 5bromo-2’-deoxyuridine (BUdR) and 5-bromouracil (BU) in 
plasma. BUdR and BU were first extracted with a mixture of ethyl acetate and X-propanol from 
plasma presaturated with solid ammonium sulfate. Following evaporation of the organic extract, the 
remaining residue was reconstituted in saturated ammonium sulfate solution, washed with a mixture 
of n-pentane-methylene chloride and re-extracted with the original solvent mixture. The organic 
extract was evaporated, reconstituted in mobile phase and chromatographed on a regular-bore ODS 
HPLC column using ultraviolet absorbance detection. The BUdR and BU quantification limits were 
both 0.1 fl, the mean intra-assay coefficients of variation were 5.0 and 5.6%, respectively, and the 
mean inter-assay coefficients of variation were 5.4 and 10.7%, respectively. This method was used to 
determine steady-state femoral arterial and hepatic venous plasma concentrations of BUdR and BU 
in a patient receiving a continuous intravenous infusion of BUdR (20 mg/kg per day). 
INTRODUCTION 
In 1960, the thymidine analogue, 5-bromo-2’ -deoxyuridine (BUdR, Fig. 1) was 
reported to enhance the radiosensitivity of cells [ 11. Recently, BUdR has been 
used clinically in the radiation treatment of osteosarcoma [ 21 and glioma [ 3,4]. 
BUdR is incorporated into DNA during the S-phase of the cell cycle [5]. Radi- 
osensitization is presently thought to result from the reaction of incorporated 







Fig. 1. Structures of 5-bromo-2’-deoxyuridine (BUdR) and 5-bromouracil (BU). 
BUdR with radiation-induced hydrated electrons, producinguracilyl radicals and 
halide ions. These reactive intermediates abstract hydrogen atoms from adjacent 
deoxyribose moieties causing DNA strand breakage [ 61. BUdR incorporation has 
also been used to estimate in vivo tumor growth fractions and cell cycle time 
following its intravenous administration to patients [ 5,7]. Recently developed 
monoclonal antibodies against BUdR have facilitated its use for the detection of 
DNA replication [ 8-101. 
BUdR is primarily metabolized by pyrimidine phosphorylases in man to form 
5-bromouracil (BU, Fig. 1) [ 11,121. These enzymes have also been reported to 
catalyze the conversion of a related compound, 5- (2-bromovinyl)uracil, to form 
5- (2-bromovinyl) -2’ -deoxyuridine [ 131. However, there have been no reports of 
the regeneration of BUdR from BU in man. 
Analytical methods employing high-performance liquid chromatography 
(HPLC) have been previously reported for the determination of BUdR in serum 
or plasma [ 3,14,15]. However, these methods required complicated HPLC col- 
umn washing [ 141 and were insensitive [ 3,151 and confounded by endogenous 
components at low BUdR plasma concentrations [ 151. 
An improved HPLC assay for the quantification of BUdR and BU in plasma 
has been developed. 
EXPERIMENTAL 
Reagents and chemicals 
Methylene chloride, 2-propanol and ammonium sulfate were purchased from 
Fisher Scientific (Fair Lawn, NJ, U.S.A. ). Ethyl acetate, n-pentane, 1 M sodium 
hydroxide and anhydrous sodium acetate were obtained from J.T. Baker (Phil- 
lipsburg, NJ, U.S.A.). Methanol was purchased from Mallinckrodt (Paris, KY, 
U.S.A. ). Tetrabutylammonium hydrogen sulfate was obtained from Aldrich 
(Milwaukee, WI. U.S.A. ). 
High-performance liquid chromatography 
The HPLC instruments included a Model M-6000A pump and a Model 990 
photodiode array detector (Waters Assoc., Milford, MA, U.S.A.) and a Model 
7125 injector (loo-p1 loop; Rheodyne, Cotati, CA, U.S.A. ). The HPLC column- 
mobile phase combination presently reported was previously described for the 
quantification of theophylline [ 161. An Ultrasphere@ ODS HPLC column was 
used (5 ,um particle size, 250 mm x 4.6 mm I.D.; Beckman Instruments, Berkeley, 
CA, U.S.A.). The mobile phase consisted of aqueous lOm# sodium acetate and 
5 mM tetrabutylammonium hydrogen sulfate (adjusted to pH 4.75 with 1 M SO- 
dium hydroxide or glacial acetic acid)-methanol (88:12, v/v). The aqueous SO- 
lution and methanol were separately filtered (Nylon-66 filters, 0.45 ,um pore size; 
Rainin Instruments, Woburn, MA, U.S.A.) prior to being mixed. The column 
temperature was maintained at 23°C with a water jacket connected to a temper- 
ature-controlled recirculation apparatus (MGW, Lauda RC3, Model T-2, Brink- 
man, Westbury, NY, U.S.A.). Other HPLC conditions included a mobile phase 
flow-rate of 1.0 ml/min and UV absorbance measurement at 290 nm. 
Extraction 
Ammonium sulfate (1 g), sample plasma (1 ml) and the aqueous internal stan- 
dard 5iodouracil (IU) (0.1 ml, 5 pug) were added to PTFE-lined screw-capped 
glass tubes (15 ml). The aqueous plasma layers were extracted twice with 5 ml of 
the solvent mixture ethyl acetate-2propanol (80:20, v/v) by mixing (10 min, 
shaker, Eberbach, Ann Arbor, MI, U.S.A.) and centrifuging (2000 g, 10 min, 
Sorvall Model RC-3, Ann Arbor, MI, U.S.A. ). The organic layers were decanted 
into clean glass tubes (15 ml) and evaporated to dryness at 23 >C, under vacuum 
(SpeedVac concentrator, Model SVC 200h-115, Savant Instruments, Hicksville, 
NY, U.S.A. ). The remaining residues were reconstituted in saturated ammonium 
sulfate solution (0.5 ml) and twice washed with the solvent mixture methylene 
chloride-n-pentane (50:50, v/v) by mixing for 10 min. After each wash the or- 
ganic layers were separated from the aqueous layers by standing for 1 min, then 
aspirated and discarded. The remaining aqueous layers were subsequently twice 
re-extracted with 5 ml of the original solvent mixture [ethyl acetate-2-propanol 
(80:20, v/v) ] by mixing (10 min) and centrifuging ( 10 min). The organic layers 
were decanted into clean glass tubes (15 ml) and evaporated to dryness under 
vacuum at 23 3 C. The tubes were capped and stored at - 20’ C. The residues were 
reconstituted in mobile phase (0.1 ml) prior to HPLC analysis. 
Extraction efficiencies 
The percent recoveries of BUdR, BU and IU from plasma were determined 
subsequent to the HPLC analysis of spiked plasma extracts (0.1-50 puM) com- 
prising the BUdR and BU calibration curves. The peak areas of BUdR, BU and 
IU were compared to their respective peak areas following the direct HPLC anal- 
ysis of an organic solution containing an equivalent amount of BUdR, BU and 
IU. 
Application of the method 
A 66-year-old male (70 kg) with a colonic malignancy and hepatic metastases 
was administered BUdR by continuous intravenous infusion (20 mg/kg per day, 
IMed-960 continuous infusion pump). Blood samples (10 ml) were obtained, via 
catheters, simultaneously from the femoral artery and hepatic vein at 75,90,105 
and 120 min after the start of the infusion. All blood samples were collected in 
polypropylene syringes containing EDTA (10 ml, Monovette, Sarstedt, Prince- 
ton, NJ, U.S.A.) and centrifuged (2000 g, 10 min, 4°C). The plasma was trans- 
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ferred to polypropylene tubes (5 ml, serum/plasma filter for Monovette, Sarstedt ) 
and stored at - 20” C until analysis. 
RESULTS AND DISCUSSION 
Chromatograms 
Control blank plasma, blank plasma spiked with BUdR and BU (both varying 
between 0.1 and 50 $W) and plasma samples from a 66-year-old male patient (70 
kg) administered BUdR by continuous intravenous infusion (20 mg/kg per day) 
were extracted and analyzed by HPLC. Typical chromatograms (Fig. 2) show 
that there were no significant endogenous components in the blank plasma ex- 
tract (Fig. 2A) which had retention times similar to that of BUdR in either the 
spiked or patient plasma extracts (peak c, Fig. 2B and C ) . There were two minor 
endogenous peaks in the blank plasma extract (Fig. 2A) which had retention 
times similar to that of BU in both the spiked and patient plasma extracts (peak 
a, Fig. 2B and C) . Interference by these two endogenous components in the quan- 
titation of BU was minimized by measuring the UV absorbance of the HPLC 
eluent at 290 nm. The wavelengths of maximum UV absorbance for BUdR and 
BU were 280 and 276 nm, respectively. However, the decreased absorptivity (i.e. 
sensitivity of detection) of BUdR and BU at 290 nm was marginal (19 and 36%, 
respectively) compared to the decreased absorptivity of these interfering com- 
ponents (66%). There were also several endogenous components in the blank 






Fig. 2. Chromatograms of plasma extracts. (A) Blank plasma; (B) plasma spiked with BUdR and 
BU, both 0.1 m (C) hepatic venous plasma (t= 75 min) from a patient infused intravenously with 
BUdR (20mg/kgperday). Peaks: a=BU;b=IU (internalstandard, ,ug);c=BUdR. 
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Fig. 2B and C). Since the amount of IU (5 pug) was much greater compared to 
the amount of these endogenous components, any interference was negligible. 
Extraction efficiencies 
The mean percentage recoveries of BUdR and BU as well as the internal stan- 
dard IU from plasma were determined after the HPLC analysis of spiked plasma 
extracts containing BUdR and BU (0.1-50 pA4) and IU (5 pg) for three consec- 
utive calibration curves. The peak areas of BUdR, BU and IU (corrected for the 
fraction of the extract injected) were compared to their respective peak areas 
following the direct HPLC analysis of an organic solution containing an equiva- 
lent amount of BUdR, BU and IU. Mean recoveries of BUdR and BU (0.1-50 
pA4) and IU from plasma were determined to be 90.7, 82.1 and 71.7%, respec- 
tively, with coefficients of variation (C.V.) less than 15% (Table I}. However, 
the recovery of BUdR was found to range between 83.2% (0.5 fl) and 93.6% 
(50 ,&f) and that of BU between 75.6% (0.5 @4) and 91.1% (50 @4). The 
extraordinarily high apparent recovery of 101.0% for BUdR at 0.1 pM is difficult 
to explain considering that there were no apparent endogenous components in- 
terfering with the determination of BUdR, as previously discussed. We attributed 
TABLE I 
MEAN PERCENTAGE RECOVERIES (DAYS l-3) OF BUdR, BU AND THE INTERNAL 
STANDARD IU FROM PLASMA 









BUdR 0.1 101.0 13.6 8 
0.5 83.2 12.4 9 
1 83.5 7.7 9 
5 90.8 9.9 9 
10 92.1 9.9 9 
50 93.6 6.5 9 
Mean 90.7 10.0 
BU 0.1 58.2 42.6 9 
0.5 75.6 9.5 8 
1 85.1 12.1 9 
5 90.4 5.8 9 
10 91.9 8.4 9 
50 91.1 6.7 9 
Mean 82.1 14.2 
0.1 66.6 5.0 9 
0.5 66.5 5.3 9 
1 69.9 11.5 9 
5 76.5 7.2 9 
10 75.3 6.9 9 
50 75.5 9.8 9 
Mean 71.7 9.6 54 
IU (5 .m9) 
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the apparent low recovery of 58.2% for BU at 0.1 ,uM to result from the under- 
estimation of the BU peak area due to the interfering endogenous components. 
Calibration curves 
Calibration curves for BUdR and BU were obtained by fitting a quadratic func- 
tion, y = a+ bx + cx2, to the values of plasma concentration x (BUdR or BU, 0. l- 
50 pM) and peak-area ratio y [ (BUdR or BU peak area/IU peak area) x 1001 
using weighted l/y:) non-linear regression [ 171. The regression coefficients a, b 
and c for three consecutive BUdR and BU calibration curves are shown in Table 
II. All three calibration curves for BUdR showed positive a coefficients and po- 
TABLE II 
PARAMETERS OF THE QUADRATIC FIT TO THE VALUES OF PEAK-AREA RATIO AND 
PLASMA CONCENTRATION FOR BUdR AND BU 
y=a+bx+cx’, where y is the peak-area ratio (x100), x is the plasma concentration (0.1-50 puM) 











a b C 
0.2116 7.124 0.006805 
(0.02302) (0.09533) (0.007370) 
0.1118 5.913 0.001940 
(0.02256) (0.08457) (0.003398) 
0.1596 4.889 0.01120 
(0.02048) (0.08387) (0.003558) 
0.05107 4.276 - 0.002360 
(0.01654) (0.07910) (0.00309) 
-0.1310 3.720 0.002360 
(0.01640) (0.1054) 0.004454) 
- 0.2406 4.040 -0.0006339 
10.007614) (0.06016) (0.002507) 
TABLE III 
GOODNESS-OF-FIT STATISTICS FOR THE QUADRATIC FIT TO THE VALUES OF PEAK- 
AREA RATIO AND PLASMA CONCENTRATION FOR BUdR AND BU 
y=a+ bx+cx’, where y is the peak-area ratio (x100), x is the plasma concentration (0.1-50 PM) 
and a, b and c are regression coefficients. 
Analyte Day Standard deviation Coefficient of 
determination 
BUdR 1 0.07988 0.9995 
2 0.07711 0.9995 
3 0.07120 0.9992 
Mean 0.0761 0.9994 
BU 1 0.05528 0.9992 
2 0.04820 0.9982 
3 0.01796 0.9995 
Mean 0.0405 0.9990 
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TABLE IV 
INVERSELY ESTIMATED PLASMA CONCENTRATIONS OBTAINED FROM THE QUA- 
DRATIC FIT TO THE VALUES OF PEAK-AREA RATIO AND PLASMA CONCENTRATION 
FOR BUdR AND BU 
Inverselv estimated plasma concentrations were estimated by the equation x= { - b+ 
d’ [b2-4c(a-y)]}/2cwhereyis thepeak-area ratio (XlOO),ris theplasma concentration (0.1-50 
,&f) and a, b and c are regression coefficients. The quadratic fit was y = a + bx + cx*, where y is the 
peak-area ratio ( x loo), x is the plasma concentration (0.1-50 PM), and a, b and c are regression 
coefficients. 
Day Actual Mean predicted Mean percentage C.V. n 
concentration concentration of theoretical (S) 



































































































































































ESTIMATED PLASMA CONCENTRATIONS OF QUALITY CONTROL SAMPLES FOR BUdR 
AND BU 


















































































































Mean 97.8 10.7 
sitive c coefficients. The positive y-axis intercepts were probably due to what 
appeared to be greater recovery of BUdR at 0.1 PM, while the positive curvature 
of the regression lines could be readily explained by the observed increase in 
percentage recovery of BUdR with increased plasma concentration. Two of the 
three calibration curves for BU showed negative a coefficients (y-axis intercepts) 
and negative c coefficients (negative curvature). This was likely the result of the 
apparent decreased percentage recovery of BU at 0.1 PM, as previously discussed. 
The BUdR and BU calibration curves displayed excellent quadratic fits, as 
shown by the goodness-of-fit statistics in Table III. The mean standard devia- 
tions of the data for three consecutive BUdR and BU calibration curves were 
0.0761 and 0.04505, respectively, while the mean coefficients of determination 
were 0.9994 and 0.9990, respectively. 
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Fig. 3. Plots of BUdR and BU plasma concentration in the femoral artery (FA) and hepatic vein 
(HV) versus time for a patient infused intravenously with BUdR (20 mg/kg per day). 
Intra-assay and inter-assay variation 
Inversely estimated plasma concentrations for BUdR and BU calibration curves 
were calculated with the equation 
x={ -b+J[b2-4c(a-y)]}/2c 
where x is the plasma concentration (@f), y is the peak-area ratio ( x 100) and 
a, b and c are regression coefficients. The inversely estimated plasma concentra- 
tions were subsequently expressed as a percentage of the theoretical spiked plasma 
concentrations. The mean values (days l-3) of the mean percentages of the the- 
oretical plasma concentrations for BUdR and BU (0.1-50 @f) were 100.4 and 
100.6%, respectively (Table IV). Both BUdR and BU exhibited acceptable intra- 
assay (within-day) variation, since the mean values (days l-3) of the mean coef- 
ficients of variation of the percentages of the theoretical plasma concentrations 
(0.1-50 PM) were less then 10% (5.0 and 5.6%, respectively, Table IV). 
The accuracies of BUdR and BU quantification were verified by estimating 
plasma concentrations of several quality control samples (0.25,2.5 and 25 @f). 
Again, the estimated plasma concentrations were expressed as percentages of the 
theoretical spiked plasma concentrations. The means (0.25-25 PM) of the mean 
percentages of theoretical for estimated plasma concentrations of BUdR and BU 
quality control samples were 98.2 and 97.8%, respectively (Table V). Coefficients 
of variation of the mean percentages of theoretical for the estimated plasma con- 
centrations of the quality control samples were used to express the inter-assay 
(between-day) variations for BUdR and BU determination. The mean values 
(0.25-25 ,&f) of the mean coefficients of variation (days l-3) were 5.4 and 10.7% 
for BUdR and BU, respectively (Table V). 
The analytical method was applied to the quantification of BUdR and BU in 
plasma obtained from the femoral artery and hepatic vein of a patient infused 
intravenously with BUdR (20 mg/kg per day). There was sufficient sensitivity 
to determine steady-state plasma concentrations of BUdR and BU in both the 
femoral artery and hepatic vein (Fig. 3 ) . This method could be applied to study- 
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